Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors

Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors

The incidence of severe immune-related adverse events (irAEs) in cancer subjects receiving immune checkpoint inhibitors (ICIs) following COVID-19 vaccination and the relationship between the incidence of severe irAE and the interval between COVID-19 vaccination and ICI dose have not been established...

Full description

Bibliographic Details
Main Authors: Danielle Gilbert, Junxiao Hu, Theresa Medina, Elizabeth R. Kessler, Elaine T. Lam
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
covid-19
vaccines
immunotherapy
checkpoint inhibitors
cancer
Online Access:http://dx.doi.org/10.1080/21645515.2023.2207438

Similar Items

Similar Items